MX2022002038A - Composicion farmaceutica para el tratamiento del insomnio. - Google Patents
Composicion farmaceutica para el tratamiento del insomnio.Info
- Publication number
- MX2022002038A MX2022002038A MX2022002038A MX2022002038A MX2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A MX 2022002038 A MX2022002038 A MX 2022002038A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- lemborexant
- pharmaceutically acceptable
- acceptable salt
- treating insomnia
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title abstract 2
- 206010022437 insomnia Diseases 0.000 title abstract 2
- MUGXRYIUWFITCP-PGRDOPGGSA-N (1r,2s)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-n-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide Chemical compound CC1=NC(C)=NC=C1OC[C@]1(C=2C=C(F)C=CC=2)[C@H](C(=O)NC=2N=CC(F)=CC=2)C1 MUGXRYIUWFITCP-PGRDOPGGSA-N 0.000 abstract 4
- 229950003528 lemborexant Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 abstract 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona una composición farmacéutica oral para tratar el insomnio, que comprende lemborexant o una sal farmacéuticamente aceptable del mismo, en donde una dosis normal del lemborexant o de la sal farmacéuticamente aceptable del mismo es de 5 a 10 mg al día, siempre que una dosis del lemborexant o de la sal farmacéuticamente aceptable del mismo sea de 2.5 mg al día cuando la composición farmacéutica se administre a un paciente junto con el agente capaz de inhibir moderada o fuertemente el CYP3A y/o una dosis del lemborexant o de la sal farmacéuticamente aceptable del mismo sea de 5 mg al día cuando la composición farmacéutica se administre al paciente junto con el agente capaz de inhibir débilmente el CYP3A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2019051141 | 2019-09-13 | ||
| PCT/US2020/046894 WO2021050219A1 (en) | 2019-09-13 | 2020-08-19 | Pharmaceutical composition for treating insomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002038A true MX2022002038A (es) | 2022-03-11 |
Family
ID=74865833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002038A MX2022002038A (es) | 2019-09-13 | 2020-08-19 | Composicion farmaceutica para el tratamiento del insomnio. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220331309A1 (es) |
| EP (1) | EP3993801A4 (es) |
| JP (1) | JP7573015B2 (es) |
| KR (1) | KR20220061950A (es) |
| CN (1) | CN114502167A (es) |
| AU (1) | AU2020347078A1 (es) |
| BR (1) | BR112022002949A2 (es) |
| CA (1) | CA3151634A1 (es) |
| MX (1) | MX2022002038A (es) |
| WO (1) | WO2021050219A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG34208A1 (en) | 1995-03-01 | 1996-12-06 | Guy Andrew Vaz | Blast and fragment resistant polyurethane boot sole for safety footwear |
| EP0828751A4 (en) | 1995-05-05 | 1999-01-20 | Human Genome Sciences Inc | HUMAN NEUROPEPTIDE RECEPTOR |
| US6159605A (en) | 1997-02-18 | 2000-12-12 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Ink-jet recording sheet |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| KR100327888B1 (ko) | 1999-07-14 | 2002-03-09 | 정숭렬 | 도로포장 파손촉진 시험장치의 무선제어 시스템 |
| CN107810006B (zh) | 2014-10-23 | 2021-03-30 | 卫材R&D管理有限公司 | 用于治疗失眠的组合物 |
| CN109640998A (zh) * | 2016-05-12 | 2019-04-16 | 卫材研究发展管理有限公司 | 治疗昼夜节律性睡眠障碍的方法 |
| WO2019024845A1 (zh) * | 2017-08-01 | 2019-02-07 | 苏州科睿思制药有限公司 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
-
2020
- 2020-08-19 CN CN202080054934.7A patent/CN114502167A/zh active Pending
- 2020-08-19 MX MX2022002038A patent/MX2022002038A/es unknown
- 2020-08-19 CA CA3151634A patent/CA3151634A1/en active Pending
- 2020-08-19 EP EP20863774.4A patent/EP3993801A4/en not_active Withdrawn
- 2020-08-19 BR BR112022002949A patent/BR112022002949A2/pt unknown
- 2020-08-19 AU AU2020347078A patent/AU2020347078A1/en active Pending
- 2020-08-19 JP JP2022505314A patent/JP7573015B2/ja active Active
- 2020-08-19 WO PCT/US2020/046894 patent/WO2021050219A1/en not_active Ceased
- 2020-08-19 US US17/636,133 patent/US20220331309A1/en not_active Abandoned
- 2020-08-19 KR KR1020227004035A patent/KR20220061950A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022002949A2 (pt) | 2022-06-07 |
| KR20220061950A (ko) | 2022-05-13 |
| WO2021050219A1 (en) | 2021-03-18 |
| EP3993801A1 (en) | 2022-05-11 |
| EP3993801A4 (en) | 2023-07-19 |
| JP7573015B2 (ja) | 2024-10-24 |
| CA3151634A1 (en) | 2021-03-18 |
| CN114502167A (zh) | 2022-05-13 |
| JP2022547388A (ja) | 2022-11-14 |
| US20220331309A1 (en) | 2022-10-20 |
| AU2020347078A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| NZ777261A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| NZ784949A (en) | Ripretinib for treating gastrointestinal stromal tumors | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MY204827A (en) | Semaglutide in medical therapy | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2022004739A (es) | Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo. | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2016505050A5 (es) | ||
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
| JP2019535830A5 (es) | ||
| MX2022002038A (es) | Composicion farmaceutica para el tratamiento del insomnio. | |
| MX2022007304A (es) | Uso de lemborexant para tratamiento del insomnio. | |
| ZA202206042B (en) | Treating behavioral and psychological symptoms in dementia patients | |
| NZ760033A (en) | Methods to treat opioid use disorder | |
| MX2025009380A (es) | Polipéptido y sus derivados, composición que comprende los mismos, y uso de los mismos |